EDX Medical Group plc, a UK-based innovator in digital diagnostics, has announced a strategic partnership with US precision medicine leader Caris Life Sciences. The deal, which secures the exclusive distribution rights for Caris’ cutting-edge molecular profiling services in the United Kingdom and Nordic countries, marks a significant expansion in the availability of personalised cancer treatment options across these regions.
The collaboration, set to last a minimum of three years, will see EDX Medical bringing Caris’ advanced tumour profiling technology to clinicians and researchers in the UK, Sweden, Denmark, Norway, and Finland. This technology is expected to transform how cancer is diagnosed and treated, offering a more precise and individualised approach to patient care.
Caris Life Sciences, a company at the forefront of AI-driven biotech, has developed one of the world’s most comprehensive platforms for cancer analysis. Their molecular profiling services assess a tumour’s DNA, RNA, and protein levels, creating a detailed molecular blueprint that helps identify the most effective treatment options for each patient. This approach, which includes Whole Exome and Whole Transcriptome Sequencing, provides clinicians with a broader and more detailed view of the genetic landscape of a patient’s cancer, allowing for more informed treatment decisions.
Professor Sir Chris Evans, OBE, the founder of EDX Medical, hailed the partnership as a “major step forward” in the company’s mission to provide access to world-class diagnostic tools that can significantly alter patient outcomes. He emphasised the importance of using comprehensive molecular profiling, particularly in cases where a patient may only be able to provide one tumour sample and needs to start treatment urgently. “Reviewing the whole exome and transcriptome, rather than a smaller selection of genes limited by current knowledge, is clearly the most robust clinical approach,” said Professor Evans. “We could not wish for a better partner in this field than Caris.”
The deal also underscores the growing importance of personalised medicine in the fight against cancer, as advancements in genomic technologies make it possible to tailor treatments to the unique genetic makeup of each patient’s tumour. By offering Caris’ services, which include both solid tumour and liquid biopsy profiling, EDX Medical aims to enhance the ability of clinicians in the UK and Nordic countries to make more precise treatment decisions.
Dr Mike Hudson, CEO of EDX Medical, expressed pride in being selected by Caris to distribute these critical services. He noted that both companies share a commitment to providing the best possible biological information to guide patient care. “EDX Medical and Caris are pioneer companies unified by their focus on providing doctors with access to the best biological information possible from valuable human samples,” said Dr Hudson.
Caris Life Sciences President, Dr David Spetzler, also expressed enthusiasm about the partnership, highlighting its potential to improve patient outcomes by enabling clinicians to make better-informed treatment decisions. “Caris is pleased to partner with EDX Medical to distribute our molecular profiling services within the United Kingdom and Nordic countries,” said Dr Spetzler. “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.”
The agreement signals a significant advancement in the availability of personalised cancer treatment options in the UK and Nordic countries, with plans for further expansion into additional regions in the future. The move is expected to have a profound impact on the standard of care for cancer patients, offering new hope for those facing this challenging disease.